skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

12013

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer



Review

(4468) Total Article Views


Authors: Menis J, Twelves C

Published Date August 2011 Volume 2011:3 Pages 101 - 111
DOI: http://dx.doi.org/10.2147/BCTT.S21741

J Menis1, C Twelves2
1Department of Oncology, University Hospital Santa Maria della Misericordia, Udine, Italy; 2Leeds Cancer Research UK Centre, University of Leeds and St James's Institute of Oncology, Leeds, UK

Abstract: Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used in this setting, but with little evidence of clinically relevant benefit, and none have previously shown improved survival. Eribulin (Halaven®) is a nontaxane tubulin-binding agent with a novel mode of action, and was recently approved by the European Medicines Agency and US Food and Drug Agency as a single agent for patients with heavily pretreated metastatic breast cancer. This review provides an overview of the discovery, and preclinical and clinical development of eribulin, culminating in the recently published EMBRACE metastatic breast cancer study.

Keywords: eribulin, metastatic breast cancer, pretreated

Corrigendum




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • ASCO 2013 Meet the Editor

    We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).